Table III.

Patient Outcomes after Allogeneic Transplantation

Patient No.	Histological Subtype	Acute GVHD Grade	Chronic GVHD (Extensive)	Disease Status/Survival	Last Follow-up (months)
1	AITL	3	Yes	CR (died of GVHD)	10.8
2	PTCL-NOS	2	No	CR	42.4
3	PTCL-NOS	0	No	PD (died of disease)	17.1
4	T-PLL	3	Yes	PD (died of disease)	14.2
5	AITL	3	Yes	CR (died of NRM)	5.3
6	PTCL-NOS	3	No	NE (died of NRM)	1.1
7	PTCL-NOS	2	Yes	CR	52.2
8	CTCL-SS	2	Yes	CR	39.3
9	AITL	2	Yes	CR (died of NRM)	46.3
10	PTCL-NOS	2	Yes	CR	95.4
11	PTCL-NOS	0	Yes	PD (died of disease)	14.5
12	NKC-L/L	0	No	CR	49.1
13	T-PLL	0	No	PD (alive last follow-up)	13.7
14	T-PLL	2	No	CR	8.8
15	AITL	0	No	CR	25.2
16	ALCL	3	Yes	CR (died of GVHD)	45.8
17	PTCL-NOS	0	No	CR	3.4

Abbreviations: AITL=angioimmunoblastic T-cell lymphoma; ALCL=anaplastic large cell lymphoma; PTCL-NOS=peripheral T-cell lymphoma, not otherwise specified; T-PLL=T-cell prolymphocytic leukaemia; CTCL-SS = Cutaneous T-cell Lymphoma-Sezary Syndrome; NK-L/L=NK-cell leukaemia/lymphoma; GVHD=graft-versus-host disease; PD=progressive disease; CR=complete remission; NE=not evaluable; NRM=non=relapse mortality.